New product: Vyndaqel (tafamidis) 61 mg soft capsules
Tafamidis, a selective stabiliser of transthyretin, is licensed for the treatment of wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy. Treatment should be initiated under the supervision of physician knowledgeable in the management of the condition
Source:
electronic Medicines compendium
SPS commentary:
Tafamidis, a selective stabiliser of transthyretin, is licensed for treatment of wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy. Treatment should be initiated under the supervision of a physician knowledgeable in the management of the condition.